Outcomes of Continuous Ambulatory Peritoneal Dialysis in Treatment of End Stage Renal Disease in Patients Registered at Middle Euphrates Center for Peritoneal Dialysis
Keywords:
Chronic Kidney disease, End stage Renal Disease, Renal replacement Therapy, Peritoneal dialysis, CAPD.Abstract
End stage renal disease is a significant health problem worldwide, the ideal treatment option is and earlier kidney transplant but it is neither always possible nor available. Peritoneal dialysis, represents an ideal alternative to kidney transplant Different modalities of peritoneal dialysis (PD) are available. The choice of technique affected by several factors and each option must be tailored to meet patient’s needs and clinical status of the patients. Continuous Ambulatory Peritoneal Dialysis (CAPD) known as a “do it yourself” option, has appeared as a good option and alternative to hospital based or home hemodialysis with some benefits to the patients, their families and health system. In Iraq, CAPD is not widely used across the country and majority of patients still performed hospital based dialysis in many centers across the country. We conducted the present study aiming to assess the outcomes of CAPD in Patients with End Stage Renal Disease Registered in the Middle Euphrates for Peritoneal Dialysis Center in Najaf City. We included 93 adult Iraqi patients of both genders who were registered during the period 2017 – Mid-2024 included. Study findings revealed that Continuous Ambulatory Peritoneal Dialysis (CAPD) is an effective option of renal replacement therapy with important benefits to the patients and can improve their health-related quality of life with little adverse outcomes that were less frequent when compared to other modalities in other studies.
Downloads
References
Forbes A, Gallagher H. Chronic kidney disease in adults: assessment and management. Clin Med. 2020 Mar;20(2):128–32.
Eckardt KU, Berns JS, Rocco M V, Kasiske BL. Definition and classification of CKD: the debate should be about patient prognosis—a position statement from KDOQI and KDIGO. Am J kidney Dis. 2009;53(6):915–20.
Stevens PE, Ahmed SB, Carrero JJ, Foster B, Francis A, Hall RK, et al. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105(4):S117–314.
Francis A, Harhay MN, Ong ACM, Tummalapalli SL, Ortiz A, Fogo AB, et al. Chronic kidney disease and the global public health agenda: an international consensus. Nat Rev Nephrol [Internet]. 2024;20(7):473–85. Available from: https://doi.org/10.1038/s41581-024-00820-6
Foreman KJ, Marquez N, Dolgert A, Fukutaki K, Fullman N, McGaughey M, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories. Lancet. 2018;392(10159):2052–90.
Wang H, Naghavi M, Allen C, Barber RM, Bhutta ZA, Carter A, et al. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1459–544.
Fraser SD, Blakeman T. Chronic kidney disease: identification and management in primary care. Pragmatic Obs Res. 2016;7:21–32.
Spasovski G, Rroji M, Vazelov E, Basic Jukic N, Tesar V, Mugosa Ratkovic M, et al. Nephrology in the Eastern and Central European region: challenges and opportunities. Kidney Int. 2019 Aug;96(2):287–90.
Thurlow JS, Joshi M, Yan G, Norris KC, Agodoa LY, Yuan CM, et al. Global epidemiology of end-stage kidney disease and disparities in kidney replacement therapy. Am J Nephrol. 2021;52(2):98–107.
Mansour N, Khalleefah M, Soliman N, Shaglabow S, Abdulgadir S, Ramdan A. Association of Gender, Age, Physiological, and Biochemical Parameters among Chronic Renal Failure Patients at Zawia Kidney Hospital. Khalij-Libya J Dent Med Res. 2023;171–7.
Putri RGP, Sholikhah A, Sukirto N. Risk Factor for Erythropoietin Resistance in Hemodialysis Patient: Literature Review. Ahmad Dahlan Med J. 2020;1(2):33–49.
Dusso A, Bauerle KT, Zhang RM, Bernal-Mizrachi C. Vitamin D and renal disease. In: Feldman and Pike’s Vitamin D. Elsevier; 2024. p. 587–618.
Rawshani A, Rawshani A, Franzén S, Sattar N, Eliasson B, Svensson AM, et al. Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2018 Aug;379(7):633–44.
Daugirdas JT. Hemodialysis treatment time: as important as it seems? In: Seminars in dialysis. Wiley Online Library; 2017. p. 93–8.
Fourtounas C, Hardalias A, Dousdampanis P, Savidaki E, Vlachojannis JG. Intermittent peritoneal dialysis (IPD): an old but still effective modality for severely disabled ESRD patients. Nephrol Dial Transplant [Internet]. 2009 Oct 1;24(10):3215–8. Available from: https://doi.org/10.1093/ndt/gfp244
Njue E, Mkrttchyan A, Tang S. Automated cyclers for Peritoneal Dialysis. Appl Perit Dial Improv Patient Outcomes. 2021;53–8.
Shi X, Du H, Zhang Z, Zhou Y. Clinical outcomes of automated versus continuous ambulatory peritoneal dialysis for end-stage kidney disease: protocol of a systematic review and meta-analysis. BMJ Open. 2022;12(11):e065795.
Davenport A. Continuous Ambulatory Peritoneal Dialysis. In: Knechtle PJM and SJ, editor. Kidney Transplantation–Principles and Practice (Seventh Edition), 2014. 7th ed. Netherland: Elsevier Inc.; 2014. p. 134–6.
Vale L, Cody J, Wallace S, Daly C, Campbell M, Grant A, et al. Continuous ambulatory peritoneal dialysis (CAPD) versus hospital or home haemodialysis for end-stage renal disease in adults. Cochrane database Syst Rev. 2004 Oct;2004(4):CD003963.
Chogtu B, Prabhu A R, Lakshmi R V, Magazine R. Early referral in chronic kidney disease―seizing the opportunity. Clin Epidemiol Glob Heal [Internet]. 2024;28:101711. Available from: https://www.sciencedirect.com/science/article/pii/S2213398424002070
Tang SCW, Lai KN. Peritoneal dialysis: the ideal bridge from conservative therapy to kidney transplant. Vol. 33, Journal of Nephrology. 2020. p. 1189–94.
Chou YH, Chen YM. Aging and Renal Disease: Old Questions for New Challenges. Aging Dis. 2021 Apr;12(2):515–28.
Cobo G, Hecking M, Port FK, Exner I, Lindholm B, Stenvinkel P, et al. Sex and gender differences in chronic kidney disease: Progression to end-stage renal disease and haemodialysis. Vol. 130, Clinical Science. 2016. p. 1147–63.
AlMojalled RM, Almabadi RM, Alghamdi AA, Alnugali RZ. Correlation of Serum Albumin Levels With Laboratory Parameters in Automated Peritoneal Dialysis and Continuous Ambulatory Peritoneal Dialysis Patients: A Prospective Cohort Study. Cureus. 2023 Oct;15(10):e47364.
Guney I, Solak Y, Atalay H, Yazici R, Altintepe L, Kara F, et al. Comparison of effects of automated peritoneal dialysis and continuous ambulatory peritoneal dialysis on health-related quality of life, sleep quality, and depression. Hemodial Int. 2010 Oct;14(4):515–22.
Ng JKC, Than WH, Szeto CC. Obesity, weight gain, and fluid overload in peritoneal Dialysis. Front Nephrol. 2022;2:880097.
Kim JK, Song YR, Lee HS, Kim HJ, Kim SG. Repeated bioimpedance measurements predict prognosis of peritoneal dialysis patients. Am J Nephrol. 2018;47(2):120–9.
Tzamaloukas AH, Saddler MC, Murata GH, Malhotra D, Sena P, Simon D, et al. Symptomatic fluid retention in patients on continuous peritoneal dialysis. J Am Soc Nephrol. 1995;6(2):198–206.
Vareta G, Georgianos PI, Vaios V, Sgouropoulou V, Roumeliotis S, Georgoulidou A, et al. Epidemiology of Hypertension among Patients on Peritoneal Dialysis Using Standardized Office and Ambulatory Blood Pressure Recordings. Am J Nephrol [Internet]. 2022 Apr 12;53(2–3):139–47. Available from: https://doi.org/10.1159/000521861
Wu J, Zhan X, Wen Y, Wang X, Feng X, Peng F, et al. Preexisting Cardiovascular Disease, Hypertension, and Mortality in Peritoneal Dialysis. RCM. 2023;24(1):30-9.
